Clinical trials: Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants…
- Trial name
- NCT04850118
- Testing
- rAAV2tYF-GRK1-hRPGRco, Control
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 85 people
- Sponsor
- Beacon Therapeutics
Retinitis Pigmentosa
Stress and Vision Fluctuations in Retinitis Pigmentosa
Retinitis pigmentosa (RP) patients experience a slowly progressive, unpredictable loss of vision which eventually leads to bare or no light perception, posing a continuous threat to patients' independence.
- Trial name
- NCT00475254
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Retinitis Pigmentosa 11, Retinitis Pigmentosa
Natural History Study of Retinitis Pigmentosa Type 11
Observational study of patients with retinitis pigmentosa type 11
- Trial name
- ReSa (NCT04805658)
- Testing
- Clinical examinations
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
Retinitis Pigmentosa
Observational Study of the Argus® II Retinal Prosthesis System
The Argus II Retinal Implant is a revolutionary new device, which offers vision to patients who are blind from retinal degeneration - retinitis pigmentosa. These patients have no alternatives.
- Trial name
- NCT01999049
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses.
- Conditions
- Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies
- Trial name
- AURORA (NCT04123626)
- Testing
- QR-1123
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- ProQR Therapeutics
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447980
- Testing
- NT-501
- Where
- 12 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurotech Pharmaceuticals
Retinitis Pigmentosa
Promising ROd-cone DYstrophy Gene therapY
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a…
- Trial name
- PRODYGY (NCT05748873)
- Testing
- SPVN06
- Where
- 6 sites in United States, France
- Volunteers
- 33 people
- Sponsor
- SparingVision
X-Linked Retinitis Pigmentosa
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
- Trial name
- HORIZON (NCT03316560)
- Testing
- rAAV2tYF-GRK1-RPGR
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beacon Therapeutics
Retinitis Pigmentosa Associated With CNGB1 Mutations
CNGB1 and Allied Disorders
Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision.
- Trial name
- NCT04639635
- Testing
- No intervention, this is a natural history progression study
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 20 people
- Sponsor
- Columbia University
Retinitis Pigmentosa
Argus® II Retinal Stimulation System Feasibility Protocol
Investigational Phase of the Study: The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis…
- Trial name
- NCT00407602
- Testing
- Implant of Argus II Retinal Prosthesis
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 30 people
- Sponsor
- Second Sight Medical Products
Retinitis Pigmentosa
BS01 in Patients With Retinitis Pigmentosa
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
- Trial name
- NCT04278131
- Testing
- BS01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bionic Sight LLC
Retinitis Pigmentosa
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases
Retinitis Pigmentosa (RP) is the most common form of hereditary retinal degeneration, with a worldwide prevalence of 1:3500. It is one of the most genetically heterogenous conditions in humans, with over 100 causative genes and…
- Trial name
- NCT02309866
- Testing
- Genetic testing
- Volunteers
- 100 people
- Sponsor
- Hillel Yaffe Medical Center
Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye.
- Trial name
- NCT05392751
- Testing
- EA-2353
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Endogena Therapeutics, Inc
Retinitis Pigmentosa
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases.
- Trial name
- NCT03944239
- Testing
- Retinal pigment epitheliums transplantation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Qi Zhou
Retinitis Pigmentosa
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading…
- Trial name
- NCT03349242
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- MeiraGTx UK II Ltd
Retinitis Pigmentosa
Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa
The purpose of this study is to investigate the role of continuous oxygen therapy combined with blue light deprivation in prevention and control of retinitis pigmentosa, in order to find a new strategy of treatment for retinitis…
- Trial name
- NCT02465749
- Testing
- Continuous oxygen, blue light-absorbing sunglasses, Compound thrombosis capsule sig: 1.5g/tid
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sun Yat-sen University
Low Vision, Retinitis Pigmentosa
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Purpose: To validate a newly developed battery of performance-based tests of visual function to be presented using virtual reality.
- Conditions
- Low Vision, Retinitis Pigmentosa, Stargardt Disease 1, Stargardt Disease 3
- Trial name
- NCT04281732
- Testing
- Virtual Reality Headset based tests
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Queen's University, Belfast
X-Linked Retinitis Pigmentosa
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
- Trial name
- NCT06333249
- Testing
- rAAV2tYF-GRK1-RPGR
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Beacon Therapeutics
Usher Syndrome, Cochlear Implantation
Auditory Neural Function in Implanted Patients With Usher Syndrome
Usher syndrome (USH) causes extensive degeneration in the cochlear nerve (CN), especially in CN fibers innervating the base of the cochlea.
- Trial name
- NCT04906135
- Testing
- Experimental manipulation of stimulation parameters
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Ohio State University
Retinitis Pigmentosa
Intravitreal Injection of MSCs in Retinitis Pigmentosa
The purpose of this study is to determine the feasibility and safety of adult human bone marrow-derived mesenchymal stem cells by intravitreal injection in patients with retinitis pigmentosa.
- Trial name
- NCT01531348
- Testing
- BM-MSC
- Where
- Thailand
- Volunteers
- 14 people
- Sponsor
- Mahidol University